title: Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.
authors.forename: Michael
authors.initials: M
authors.lastname: Nauck
authors.forename: Ruth S
authors.initials: RS
authors.lastname: Weinstock
authors.forename: Guillermo E
authors.initials: GE
authors.lastname: Umpierrez
authors.forename: Bruno
authors.initials: B
authors.lastname: Guerci
authors.forename: Zachary
authors.initials: Z
authors.lastname: Skrivanek
authors.forename: Zvonko
authors.initials: Z
authors.lastname: Milicevic